This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the Clinical Evidence for CMB-305 in Soft Tissue Sarcoma

Ticker(s): IMDZ

Who's the expert?

Oncologist with significant experience treating soft tissue sarcoma, particularly synovial sarcoma and myxoid/round cell liposarcoma

Interview Questions
Q1.

How would you characterize the clinical results thus far in a Phase I study of the company's vaccine for heavily pretreated metastatic synovial sarcoma and myxoid/round cell sarcoma? Company claims their cancer vaccine in metastatic STS (synovial sarcoma and myxoid/round cell liposarcoma) (n=24), 80% 1 year survival, with 58% DCR (1 PR/13 SD), PFS 4.6 months.   

Added By: festina_lente
Q2.

Company claims as of June 2016 “mOS not reached - median follow up 640 days (21.3 months)”.  If the trial is still ongoing, does this mean that mOS is certain to be greater than 640 days (21.3 months)?

Added By: festina_lente
Q3.

What is your experience of the current toxicity of first line olaratumab and doxorubincin?

Added By: festina_lente

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.